Overexpression of neurone glial-related cell adhesion molecule is an independent predictor of poor prognosis in advanced colorectal cancer

Cancer Science

Volumn 102, Issue 10, 2011, Pages 1855-1861

  Chan, Jason Y ^a,b   Ong, Chee W ^a,b   Salto Tellez, Manuel ^a,b,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; NERVE CELL ADHESION MOLECULE; PROTEIN P53; B RAF KINASE; BRAF PROTEIN, HUMAN; CELL ADHESION MOLECULE; KRAS PROTEIN, HUMAN; NRCAM PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TUMOR MARKER;

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PERITONEUM METASTASIS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TISSUE MICROARRAY; TUMOR VOLUME; BIOSYNTHESIS; COLORECTAL TUMOR; GENETICS; GLIA; KAPLAN MEIER METHOD; METABOLISM; METASTASIS; MICROSATELLITE INSTABILITY; MIDDLE AGED; MORTALITY; MUTATION; ONCOGENE RAS; PATHOLOGY; PROGNOSIS; PROTEIN MICROARRAY; WNT SIGNALING PATHWAY;

AGED; AGED, 80 AND OVER; CELL ADHESION MOLECULES; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENES, RAS; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEUROGLIA; PROGNOSIS; PROTEIN ARRAY ANALYSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL; WNT SIGNALING PATHWAY;

EID: 84856272977     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02021.x     Document Type: Article

References (44)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Cunningham D, Atkin W, Lenz HJ et al. Colorectal cancer. Lancet 2010; 375: 1030-47.
3. Khleif SN, Doroshow JH, Hait WN, AACR-FDA-NCI Cancer Biomarkers Collaborative. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 2010; 16: 3299-318.
4. Beckman M. CAMs are stopping cancer in its metastatic tracks. J Natl Cancer Inst 2006; 98: 576-7.
5. Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006; 25: 7531-7.
6. Conacci-Sorrell ME, Ben-Yedidia T, Shtutman M, Feinstein E, Einat P, Ben-Ze'ev A. Nr-CAM is a target gene of the beta-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis. Genes Dev 2002; 16: 2058-72.
7. Li S, Jo YS, Lee JH et al. L1 cell adhesion molecule is a novel independent poor prognostic factor of extrahepatic cholangiocarcinoma. Clin Cancer Res 2009; 15: 7345-51.
8. Munz M, Baeuerle PA, Gires O. The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res 2009; 69: 5627-9.
9. Gavert N, Ben-Shmuel A, Raveh S, Ben-Ze'ev A. L1-CAM in cancerous tissues. Expert Opin Biol Ther 2008; 8: 1749-57.
10. Boo YJ, Park JM, Kim J et al. L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. Ann Surg Oncol 2007; 14: 1703-11.
11. Grumet M. Nr-CAM: a cell adhesion molecule with ligand and receptor functions. Cell Tissue Res 1997; 290: 423-8.
12. Grumet M, Mauro V, Burgoon MP, Edelman GM, Cunningham BA. Structure of a new nervous system glycoprotein, Nr-CAM, and its relationship tosubgroups of neural cell adhesion molecules. J Cell Biol 1991; 113: 1399-412.
13. Suter DM, Pollerberg GE, Buchstaller A, Giger RJ, Dreyer WJ, Sonderegger P. Binding between the neural cell adhesion molecules axonin-1 and Nr-CAM/Bravo is involved in neuron-glia interaction. J Cell Biol 1995; 131: 1067-81.
14. Sakurai T, Lustig M, Babiarz J et al. Overlapping functions of the cell adhesion molecules Nr-CAM and L1 in cerebellar granule cell development. J Cell Biol 2001; 154: 1259-73.
15. Falk J, Thoumine O, Dequidt C, Choquet D, Faivre-Sarrailh C. NrCAM coupling to the cytoskeleton depends on multiple protein domains and partitioning into lipid rafts. Mol Biol Cell 2004; 15: 4695-709.
16. Zelina P, Avci HX, Thelen K, Pollerberg GE. The cell adhesion molecule NrCAM is crucial for growth cone behaviour and pathfinding of retinal ganglion cell axons. Development 2005; 132: 3609-18.
17. Wang B, Williams H, Du JS, Terrett J, Kenwrick S. Alternative splicing of human NrCAM in neural and nonneural tissues. Mol Cell Neurosci 1998; 10: 287-95.
18. Glienke J, Schmitt AO, Pilarsky C et al. Differential gene expression by endothelial cells in distinct angiogenic states. Eur J Biochem 2000; 267: 2820-30.
19. Dhodapkar KM, Friedlander D, Scholes J, Grumet M. Differential expression of the cell-adhesion molecule Nr-CAM in hyperplastic and neoplastic human pancreatic tissue. Hum Pathol 2001; 32: 396-400.
20. Moré MI, Kirsch FP, Rathjen FG. Targeted ablation of NrCAM or ankyrin-B results in disorganized lens fibers leading to cataract formation. J Cell Biol 2001; 154: 187-96.
21. Aitkenhead M, Wang SJ, Nakatsu MN, Mestas J, Heard C, Hughes CC. Identification of endothelial cell genes expressed in an in vitro model of angiogenesis: induction of ESM-1, (beta)ig-h3, and NrCAM. Microvasc Res 2002; 63: 159-71.
22. Sehgal A, Boynton AL, Young RF et al. Cell adhesion molecule Nr-CAM is over-expressed in human brain tumors. Int J Cancer 1998; 76: 451-8.
23. Lukashova-v Zangen I, Kneitz S, Monoranu CM et al. Ependymoma gene expression profiles associated with histological subtype, proliferation, and patient survival. Acta Neuropathol 2007; 113: 325-37.
24. Liu X, Mazanek P, Dam V et al. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification. Oncogene 2008; 27: 1478-88.
25. Górka B, Skubis-Zegadło J, Mikula M, Bardadin K, Paliczka E, Czarnocka B. NrCAM, a neuronal system cell-adhesion molecule, is induced in papillary thyroid carcinomas. Br J Cancer 2007; 97: 531-8.
26. Greene FL, American Joint Committee on Cancer. American Cancer Society. AJCC Cancer Staging Manual, 6th edn. New York: Springer, SpVerlag, 2002.
27. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-16.
28. Salto-Tellez M, Nga ME, Han HC et al. Tissue microarrays characterise the clinical significance of a VEGF-A protein expression signature in gastrointestinal stromal tumors. Br J Cancer 2007; 96: 776-82.
29. Das K, Mohd Omar MF, Ong CW et al. TRARESA: a tissue microarraybased hospital system for biomarker validation and discovery. Pathology 2008; 40: 441-9.
30. Jass JR, Biden KG, Cummings MC et al. Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. J Clin Pathol 1999; 52: 455-60.
31. Ong CW, Kim LG, Kong HH et al. Computer-assisted pathological immunohistochemistry scoring is more time-effective than conventional scoring, but provides no analytical advantage. Histopathology 2010; 56: 523-9.
32. Bacani J, Zwingerman R, Di Nicola N et al. Tumour microsatellite instability in early onset gastric cancer. J Mol Diagn 2005; 7: 465-77.
33. Samowitz WS, Sweeney C, Herrick J et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005; 65: 6063-9.
34. Chung GG, Provost E, Kielhorn EP, Charette LA, Smith BL, Rimm DL. Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis. Clin Cancer Res 2001; 7: 4013-20.
35. Mårtensson A, Oberg A, Jung A, Cederquist K, Stenling R, Palmqvist R. Beta-catenin expression in relation to genetic instability and prognosis in colorectal cancer. Oncol Rep 2007; 17: 447-52.
36. Kinzler KW, Volgelstein B. The genetics basis of human cancer. Kinzler KW, Volgelstein B, eds. Colorectal Tumors. New York: McGraw-Hill, 1998; 565-87.
37. Sadot E, Geiger B, Oren M, Ben-Ze'ev A. Down-regulation of beta-catenin by activated p53. Mol Cell Biol 2001; 21: 6768-81.
38. Shtutman M, Levina E, Ohouo P, Baig M, Roninson IB. Cell adhesion molecule L1 disrupts E-cadherin-containing adherens junctions and increases scattering and motility of MCF7 breast carcinoma cells. Cancer Res 2006; 66: 11370-80.
39. Paschos KA, Canovas D, Bird NC. The role of cell adhesion molecules in the progression of colorectal cancer and the development of liver metastasis. Cell Signal 2009; 21: 665-74.
40. Conacci-Sorrell M, Kaplan A, Raveh S, Gavert N, Sakurai T, Ben-Ze'ev A. The shed ectodomain of Nr-CAM stimulates cell proliferation and motility, and confers cell transformation. Cancer Res 2005; 65: 11605-12.
41. Chan JY, Phoo MS, Clement MV, Pervaiz S, Lee SC. Resveratrol displays converse dose-related effects on 5-fluorouracil-evoked colon cancer cell apoptosis: the roles of caspase-6 and p53. Cancer Biol Ther 2008; 7: 1305-12.
42. Sehgal A, Ricks S, Warrick J, Boynton AL, Murphy GP. Antisense human neuroglia related cell adhesion molecule hNr-CAM, reduces the tumorigenic properties of human glioblastoma cells. Anticancer Res 1999; 19: 4947-53.
43. Arlt MJ, Novak-Hofer I, Gast D et al. Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment. Cancer Res 2006; 66: 936-43.
44. Min JK, Kim JM, Li S et al. L1 Cell adhesion molecule Is a novel therapeutic target in intrahepatic cholangiocarcinoma. Clin Cancer Res 2010; 16: 3571-80.